Prostate Specific Antigen (PSA), the primary means of diagnosing prostate cancer in the modern era, lacks specificity in differentiating benign from malignant disease. Thus clinical decisions based on PSA may lead to unnecessary biopsies in some while overlooking biopsies in others. p2PSA has emerged from studies looking at archived serum samples over the past several years as a better screening tool for detecting prostate cancer.
Read more at Medical News Today.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment